texas oncology more breakthroughs. more victories

Share:

 
 

Debra Patt, M.D., MPH, MBA

Debra Patt, M.D., MPH, MBA

Provider Type: Physician

Specialties:
  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Hematology
  • Internal Medicine

General Summary

Dr. Debra Patt is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer research, serves on the US Oncology Research breast cancer committee, and chairs the breast cancer subsection of the pathways task force for The US Oncology Network as well as the leader locally for breast cancer research. She has expertise in healthcare policy and has testified before Congress to protect access to care for Medicare beneficiaries. She is a leader in clinical cancer informatics, and is involved in system innovations to enhance care delivery across a national network of oncology practices. She is the Editor In Chief of the Journal of Clinical Oncology- Clinical Cancer Informatics. Her clinical informatics research focuses in imaging informatics for breast cancer, clinical decision support systems, predictive analytics to reduce risk in patients with advanced cancer, and quality improvement.

She led healthcare informatics for The US Oncology Network from 2008-2015 and continues to lead analytics as a medical director for McKesson Specialty Health. In addition to a substantial background in informatics and health economics and outcomes research, she directs public policy for Texas Oncology. Nationally, she is the past-chair of ASCO’s clinical practice committee and serves on ASCO’s nominating committee for the ASCO Board and the Conquer Cancer Foundation as well as the health IT work group, EHR, technology, and data requirements workgroup, and guidelines committees.

Dr. Patt serves on the national board for the Community Oncology Alliance and local board of The Shivers Cancer Foundation. She serves as incoming chair on the Texas Medical Association’s Council on Legislation and frequently speaks on healthcare policy at the state and federal level. She is a past chair for the Texas Medical Association’s committee on cancer and has served on the council on science and public health. She is a former board member of Komen Austin and the breast cancer resource center. Dr. Patt is a nationally recognized leader in cancer research, has published many articles, and leads the service line for breast health services for the Dell Medical School. Dr. Patt is the president-elect for the Texas Society of Clinical Oncology.

Education

  • PhD in Health Economics and Health Services Research
    In Progress
  • Master of Business Administration
    The University of Texas, Austin, TX
  • Fellowship in Hematology and Medical Oncology
    The University of Texas MD Anderson Cancer Center, Houston, TX
  • Masters of Public Health with a focus on cancer health policy
    The University of Texas Health Science Center’s School of Public Health, Houston, TX
  • Cancer Prevention Program
    National Cancer Institute, Rockville, MD
  • Residency in Internal Medicine and Pediatrics
    Baylor College of Medicine, Houston, TX
  • Medical Degree
    Baylor College of Medicine, Houston, TX 
  • Bachelor of Science in Zoology, graduated with special honors
    The University of Texas, Austin, TX

Medical Practice

Research Interest

Surgery Locations

Other Information

Dr. Patt is married to Hanoch Patt, M.D., a pediatric cardiologist in Austin. They have three children.


Dr. Patt testifying before Congress to protect cancer care for Medicare beneficiaries.

Accolades & Memberships

  • American Society of Clinical Oncology Nominating Committee
  • ASCO Young Investigator’s Award
  • Community Oncology Alliance Board of Directors
  • Completed the ASCO Leadership Development Program
  • Fellow of the Year at The University of Texas MD Anderson Cancer Center in Research for her excellence in breast cancer research
  • Jesse H. Jones Fellowship in Cancer Education at The University of Texas MD Anderson Cancer Center
  • Shivers Foundation Board of Directors
  • Texas Society of Clinical Oncology
  • Young Physician of the Year Award in Travis County

Community Service

Videos:

Publications

  • Magnetization Transfer MRI of Breast Cancer in the Community Setting: Reproducibility and Preliminary Results in Neoadjuvant Therapy.

    Tomography, 2019

  • Cancer Informatics in 2018: The Mysteries of the Cancer Genome Continue to Unravel, Deep Learning Approaches the Clinic, and Passive Data Collection Demonstrates Utility.

    Yearbook of Medical Informatics, 2019

  • Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

    Support Care Cancer, 2019

  • FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

    Annals of Oncology, 2019

  • Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology.

    American Society of Clinical Oncology Educational Book, 2019

Show all Publications
  • Recent study on site of care has severe limitations.

    American Journal of Managed Care, 2018

  • Clinical Challenges and Opportunities With Current Electronic Health Records: Practicing Oncologists' Perspective.

    Journal of Oncology Practice, 2018

  • Cancer Informatics in 2017: A New Beginning and a Bright Future.

    Yearbook of Medical Informatics, 2018

  • Debra Patt on How the Management of Cancer is Changing as Patients Live Longer.

    Oncology, 2018

  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

    Journal of Clinical Oncology, 2018

  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

    Journal of Clinical Oncology, 2018

  • Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.

    Clinical Breast Cancer, 2018

  • Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting.

    Journal of Magnetic Resonance Imaging, 2018

  • Measuring Quality Is Complicated.

    Journal of Oncology Practice, 2018

  • Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.

    Journal of Medical Imaging, 2018

  • Understanding Utilization Management Policy: How to Manage This Increasingly Complex Environment in Collaboration and With Better Data.

    American Society of Clinical Oncology Educational Book, 2018

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet Oncology, 2017

  • Our Journey Begins.

    JCO Clinical Cancer Informatics, 2017

  • The Road of Mentorship

    American Society of Clinical Oncology Educational Book, 2017

  • More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice.

    American Society of Clinical Oncology Educational Book, 2017

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer

    Clinical Cancer Research, 2017

  • HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes

    Drugs Real World Outcomes, 2017

  • Utilization management in oncology.

    Journal of Clinical Oncology, 2017

  • Her 2-positive metastatic breast cancer patients receiving pertuzumab in a community oncology practice setting: Treatment patterns and outcomes.

    Drugs Real World Outcomes, 2017

  • Better Screening Using Big Data.

    Journal of Oncology Practice, 2016

  • Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors with Chemotherapy for Breast Cancer

    Journal of Clinical Oncology, 2016

  • The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting

    Clinical Lymphoma, Myeloma & Leukemia, 2015

  • Treatment of Metastatic Breast Cancer with 𝑛𝑎𝑏-paclitaxel in the Community Practice Setting: a US Oncology Survey.

    The Journal of Community and Supportive Oncology, 2015

  • Bridging the Medical Education and Quality Cancer Care Divide: A Call to Action

    Journal of Oncology Practice, 2015

  • The treatment patterns, efficacy, and safety of nab-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.

    BMC Cancer, 2015

  • Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

    Journal of the National Comprehensive Cancer Network, 2015

  • Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.

    Leukemia & Lymphoma, 2015

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

    Journal of Clinical Oncology, 2015

  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline.

    Journal of Clinical Oncology, 2014

  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

    Journal of Clinical Oncology, 2014

  • Taking on racial and ethnic disparities in cancer care.

    Journal of Community and Supportive Oncology, 2014

  • Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.

    Oncologist, 2013

  • Defining cancer care quality or delivering quality cancer care?

    Journal of the National Comprehensive Cancer Network, 2013

  • Evaluating Use Characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early stage breast cancer.

    Journal of Oncology Practice, 2013

  • Women in Oncology

    American Society of Clinical Oncology Educational Book, 2013

  • Thoughts and recommendations on cancer care site of service

    Community Oncology, 2012

  • Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in 2 Distinct Databases

    Journal of Oncology Practice, 2011

  • Benchmarks for value in cancer care: an analysis of a large commercial population.

    Journal of Oncology Practice, 2011

  • Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community.

    JCO supplements, 2011

  • Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.

    JCO supplements, 2011

  • Understanding male breast cancer in the community setting.

    JCO supplements, 2011

  • Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community.

    JCO supplements, 2011

  • Pathways, Outcomes, and Costs in Colon Cancer: Retrospective evaluations in two distinct databases.

    Journal of Oncology Practice, 2011

  • Iniparib plus Chemotherapy n Metastatic TripleNegative Breast Cancer.

    The New England Journal of Medicine, 2011

  • Randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.

    Journal of Thoracic Oncology, 2010

  • Ixabepilone alone and in combination with chemotherapy in the community setting.

    Proceedings ASCO Breast Cancer Symposium, 2010

  • Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network.

    Journal of Clinical Oncology, 2010

  • Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk.

    Journal of Clinical Oncology, 2007

  • Paclitaxel in Breast Cancer.

    Women's Health, 2006

  • Cardiac morbidity of adjuvant radiotherapy in patients with early stage breast cancer.

    Journal of Clinical Oncology, 2005

  • Trends to protect workers from job related secondhand smoke in Texas.

    Texas Medicine, 2005